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Investigating the Localization and Function of PKHD1L1 as a Possible Tumor
Suppressor

Sydney Nyquist
Project Advisor: Dr. Lina Yoo
Department of Biology, Denison University

Abstract
Polycystic Kidney and Hepatic Disease 1-like 1 (PKHD1L1) has been found to be
mutated in many different types of cancers. Its mutation and downregulation have led to
the belief that it is a tumor suppressor gene. Preliminary research suggests that this gene
may be involved with regulating cell growth or movement. The objective of this study is
to determine the function of PKHD1L1 and its localization within mammalian cells. A
variety of human cells were utilized: bladder cells (UM-UC-3), kidney cells (HEK 293),
and breast cells (AG11138). Experiments done with mutant knockout UM-UC-3 cells
indicate that loss of PKHD1L1 may increase cell proliferation and that its regulation may
be density dependent. Localization was unable to be determined due to significant cell
death after puromycin selection, but an examination of PKHD1L1’s expression
demonstrated that the gene is expressed within HEK 293 and AG11138 cells. While this
research lays the groundwork for investigation into PKHD1L1’s function and location,
more studies are required in order to draw solid conclusions on its role within the cell and
in relation to tumor suppression.
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Introduction
Cancer and tumor suppressors
Cancer is a common diagnosis in today’s society. In the United States alone,
approximately 39.5% of the population will receive a cancer diagnosis at some point in
their lives (National Cancer Institute, 2015). Cancer comes in many different forms and
can affect different tissues. It begins as a tumor, which occurs when cells divide out of
control. Normally, cells have genes that regulate their growth and division so this does
not occur. Some of these genes act as barriers against irregular growth and are able to
slow or pause cell division, induce apoptosis (programmed cell death), and repair
damaged DNA. These genes are known as tumor suppressors (Cooper, 2000). When
these genes are damaged or mutated, the likelihood of tumors, and cancer, increases. One
example of a well-known tumor suppressor occurs in retinoblastoma. In order to develop
retinoblastoma, two mutations of the Rb gene are necessary. If there is one functional Rb
copy, the gene is able to suppress the growth of tumors and retinoblastoma will not
develop. For inherited retinoblastoma, one nonfunctional copy of Rb is inherited and the
other must be mutated for tumor development (American Cancer Society, 2021). This
revelation on the relationship between Rb and retinoblastoma gave much insight into
tumor suppressors and their existence.
Due to their great influence, tumor suppressor genes are a point of interest for
many researchers as they indicate functions that without which the cells become more
prone to tumor formation. Knowing which functions suppress tumor formation gives
more insight into how cancer may be prevented and also what the underlying causes of
tumor and cancer formation are.
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One method of identifying genes that may be possible tumor suppressors is by
looking at the mutation rates of genes in different types of cancers. If a gene has a high
mutation rate that results in lower gene expression or a nonfunctional protein for a
specific cancer, it stands to reason that the mutation of this gene allows for tumor
formation. In other words, tumors are more likely to form when the gene is not
functioning normally. In this way, possible tumor suppressor genes can be identified
using databases such as that of The Cancer Genome Atlas Program by the National
Cancer Institute.

PKHD1L1 and relevant research
One gene we identified as being a possible tumor suppressor is Polycystic Kidney
and Hepatic Disease 1-like 1 (PKHD1L1). This specific gene had a high mutation rate in
multiple epithelial cancers (Shi and Yoo, 2018). This led us to believe that for these types
of cancers, PKHD1L1 may play an important role in tumor suppression. Unfortunately,
not much is known about PKHD1L1. Originally believed to be a mouse gene, PKHD1L1
is located on chromosome 8 of the human genome. Most knowledge of PKHD1L1 comes
from its role as a coat protein in hair stereocilia. In mice, PKHD1L1 has been shown to
make up the surface coat of hair cell stereocilia (Ivanchenko et al., 2020). It also seems to
be a large, mainly extracellular protein that is required for normal hearing in mice (Wu et
al., 2019). Although this gives us some information about PKHD1L1’s possible function,
it does not answer any questions about how it may function as a tumor suppressor.
The research done on PKHD1L1 as it relates to cancer is very limited. Much of
this research stems from seeing a correlation between the mutation rate of PKHD1L1 and

5

the occurrence of cancer. One group of researchers, while examining patterns in
metastatic triple-negative breast cancer, found that PKHD1L1 was one of the genes
whose mutation correlated with tumor occurrence (Saravia et al., 2019). Another research
group, while examining lung adenocarcinoma (LUAD), found that PKHD1L1 was
associated with LUAD and that some of its mutation sites were related to its gene
expression (Wang et al., 2020). While these associations further support that PKHD1L1
is a tumor suppressor, they do not tell us what its function is or how it relates to cancer
formation.
There is some literature that pertains to how PKHD1L1 functions within a cell
and how its loss of function relates to tumor formation. One paper examined PKHD1L1’s
possible role in thyroid cancer. The researchers noticed that this gene was highly
associated with papillary thyroid cancer. Using RT-q PCR, the researchers were able to
compare PKHD1L1 expression levels between cancerous thyroid tissues and normal
thyroid tissues. They found that PKHD1L1 was significantly downregulated in the tumor
cells compared to the noncancerous cells (Zheng et al., 2019). This further suggests that
PKHD1L1 is a tumor suppressor. The same researchers also showed that when
PKHD1L1 was knocked out in cancerous thyroid cells, the migratory and invasive
abilities of these cells were increased (Zheng et al., 2019). Not only does this provide
increased evidence that PKHD1L1 functions in some way to prevent tumor formation,
but it also suggests that without PKHD1L1, tumor metastasis may be more likely.
Although the aforementioned research does present evidence that PKHD1L1 is a
tumor suppressor and even suggests what factors it may influence, there is still a large
knowledge gap. The specific functions of PKHD1L1 are not known, nor is its localization
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within the cell. This important information can then guide research on ways tumors can
be prevented. It could also reveal what functions are most important for tumor
suppression.

Research questions and objectives
Due to PKHD1L1’s position as a possible tumor suppressor and the lack of
knowledge about it, our lab chose to investigate further into PKHD1L1’s function and
role in tumor suppression. Our main question relates to function: what does PKHD1L1
do? To answer this, we began by investigating what functions would be affected by loss
of the gene. We also began attempting to determine the localization of PKHD1L1 within
human cells, believing that this would give us some clue as to its possible function. As
another way of looking at function, we also examined expression levels of the gene in
normal human cells.
Several methods were utilized to achieve these goals. The first was to create a
knockout using CRISPR-Cas9 in a bladder cell line, UM-UC-3. From there, antibodies
could be used to determine protein location. While a knockout was created by another
researcher in the Yoo lab, Katherine Lindsay, in a human bladder cell line, this was only
confirmed on the DNA level and could not be confirmed on the protein level. This
knockout was also used in a cell proliferation assay and a colony formation assay,
although the results are only moderately useful due to the unconfirmed nature of the
knockout.
The next method was used to determine localization. Using the Mendenhall and
Myers CRISPR-Cas9 system, we wanted to add a FLAG-tag to the gene. The FLAG-tag
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could then be transfected into two human cell lines, AG11138, a breast cell line, and 293,
a kidney cell line.
Our lab also sought to learn more about PKHD1L1 by looking at mRNA
expression levels in human cell lines. This would allow us to establish a baseline of
expression for PKHD1L1 in normal human cell lines. Additionally, this would allow for
verification of knockouts created.
The overarching goal of this project was to investigate PKHD1L1’s function as a
possible tumor suppressor in order to gain knowledge about what prevents and causes
tumors and cancer. Our lab hopes that this research will be taken further and that more
experiments can be run to either confirm the knockout line or to create a more successful
one. This would allow for assays- such as cell proliferation and death assays- to test for
different reactions of cells with and without PKHD1L1. It would further our
advancements in our knowledge about tumor suppressors and PKHD1L1’s role in cancer.

Methods
Cell Culture
Three different human cell types were used throughout this project: the bladder
cell line UM-UC-3, the kidney cell line HEK 293, and the breast cells AG11138. All
mammalian cells were thawed in a 37° water bath, spun down in 10mL of proper growth
medium, resuspended in 10mL of growth medium and plated on a 10cm dish.
UM-UC-3 and HEK 293 cells were cultured in DMEM (Thermofisher) and
MEM/EBSS (Cytiva Hyclone) media respectively. Media was supplemented with 1%
penicillin streptomycin antibiotic (Pen-strep) and 10% fetal calf serum (FCS). Cells were
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maintained in a 37° C incubator with 5% CO2 and humidity. They were split at about 7090% confluency by aspirating the media, washing with 5mL 1x phosphate buffered saline
(1x PBS), adding 500µL 0.25% Trypsin, then resuspending in complete growth medium.
AG11138 cells were cultured in MEBM media (Lonza) supplemented with 0.5mL
hydrocortisone, 50µl of cholera toxin, 0.5mL human Epidermal Growth Factor, 0.5mL
insulin, 2.0 mL bovine pituitary extract, and 5mL of pen-strep per 500mL of MEBM
(Lonza).

MTS assay on PKHD1L1 knockouts in UM-UC-3 cells
A cell proliferation assay (MTS) was performed upon the PKHD1L1 knockouts
created by another member of the lab. Experiment was done using the mutant knockout
UM-UC-3 cells and the parental UM-UC-3 cells. Cells were plated after trypsinization on
96 well plates at two different densities: 1.0 x 104 cells and 1.3 x 104 cells. Seven
replicates were done for both parental and mutant cells for each density. 48 hours after
plating, 20µl of a 5% PMS, 95% MTS solution were added to each well. Readings were
taken with an ELISA plate reader at 490nm absorbance at 1 hour and 2 hours, and 3
hours post addition. Readings were saved and analyzed using JMP Pro to run an ANOVA
and Tukey-Kramer post-hoc test.

Colony formation assay
Multiple colony formation assays were performed to compare the parental and
knockout UM-UC-3 cells. A cell count was performed on trypsinized cells and 100 or
200 cells were plated in six wells of a 6-well plate, three wells of parental cells and three
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wells of mutant cells. Cells were allowed to grow in 2.5mL of complete DMEM media
for 8 days before being stained with crystal violet.
Staining was done by placing the plates on ice and washing twice with 4°C PBS.
They were then fixed for 10 minutes with ice cold 100% methanol. A crystal violet
solution of 25% methanol and 0.5% crystal violet in deionized water was created. The
fixed cells were then incubated in this solution for ten minutes, and then washed until dye
stopped running. After being allowed to dry, plates were counted.

Tagging PKHD1L1
In order to insert a FLAG-tag into PKHD1L1, a target sequence must be cloned
into an sgRNA scaffold. We used Benchling to identify appropriate oligos following the
Zhang Lab general cloning protocol (Zhang lab). gRNA primers were created following
this protocol, using PAM sequence NGG and searching within -30 and +50 base pairs of
the stop codon.

Table 1. gRNA primers for PKHD1L1
Oligo pair

Sequence (5’ to 3’)

Forward 1

CACCGAAAGTGCTGTTCCGAAGAAT

Reverse 1

AAACATTCTTCGGAACAGCACTTTC

Forward 2

CACCGTTTTGTTTCAGCCTATTCTT

Reverse 2

AAACAAGAATAGGCTGAAACAAAAC

Forward 3

CACCGTTTAGTAGCTTCCTGAAAAA

Reverse 3

AAACTTTTTCAGGAAGCTACTAAAC
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pSpCas9(BB)-2A-Puro (PX459) V2.0 was the plasmid used (AddGene). For each
pair of primers, the following procedure was used, modified from the Zhang lab’s target
sequence cloning protocol (Zhang lab):
1µg of plasmid was digested for 4 hours at 37°C with 1µL BbsI, 1µg of plasmid,
2µL of 2.1 buffer, and ddH2O to achieve a 20µL reaction. The digest was gel purified
using a Thermoscientific GeneJET Gel Extraction kit and its accompanying protocol
(ThermoScientific). Meanwhile, 1µL of forward oligo (100µM) and 1µL of reverse oligo
(100µM) were annealed in a thermocycler with 1µL 10X T4 Ligation Buffer (NEB),
6.5µL ddH2O, and 0.5µL PNK (NEB). The thermocycler was run with the following
parameters: 37°C for 30 minutes followed by 95°C for 5 minutes and then ramp down to
25°C at 5°C per minute. Once both plasmid DNA and annealed oligos are ready, the
following ligation reaction was set up and incubated overnight: 50ng of digested plasmid,
1µL of a 1:200 dilution of the oligo duplex, 1µL 10X T4 DNA ligase buffer, 1µL T4
DNA ligase, and ddH2O to a 10µL reaction. This was followed by a transformation into
competent cells, first with normal E. coli and then with NEB 10-beta E. coli. The
transformed cells were selected for on ampicillin plates and colonies were plucked and
grown in LB with 100µg/mL of ampicillin. A miniprep was done using a Promega
Wizard Plus SV Miniprep kit and its accompanying protocol and purified DNA was
digested with SacI and BbsI to determine identity, as well as sequenced (ProMega).
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Transformations
Escherichia coli (E. coli) were transformed with various plasmids and used to
create plasmid DNA preparations. E. coli cells were taken from the -80°C freezer and
thawed on ice. After thawing, 75µL of thawed cells were added to each tube of plasmid
DNA. This was incubated on ice for 10 minutes and then heat shocked at 42°C in a water
bath for 45 seconds. Tubes were then placed on ice for 2 minutes. 900µL of luria broth
was added to each tube using sterile technique. The tubes were then placed in a 37°C
shaking incubator for 35 minutes before being spun down at 13,000 rpm for 2 minutes.
All but 100µL of supernatant were removed and cells were resuspended in remaining
supernatant. This was then pipetted and spread onto agar plates with 100µg/mL of
ampicillin. These were then incubated at 37°C.
NEB 10-beta E. coli cells were also obtained for transformation with large
plasmids. Cells were thawed on ice and 50µL were transferred to a separate tube for each
different transformation. 1-5µL containing 1pg-100ng of plasmid DNA was added to
each tube and flicked to mix. Tubes were placed on ice for 30 minutes before being heat
shocked in a 42°C water bath for 30 seconds. They were then incubated on ice for five
minutes without mixing. 950µL of room temperature NEB 10-beta/Stable Outgrowth
Medium (New England Biolabs) was added to each tube and shaken at 37°C for 60
minutes. Agar plates containing 100µg/mL of ampicillin were warmed to 37°C and 50100µL of each tube were spread onto the plates and incubated at 37°C. Colonies were
then plucked and miniprepped.
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Transfection
Transfections were done as part of the project attempting to localize PKHD1L1
by adding a FLAG-tag into the gene. The plasmid containing Cas9 and the generated
target sequence oligos would need to be transfected into the desired cells along with the
homology directed repair donor plasmid with proper homology arms and selection
marker. Transfection was done on HEK 293 kidney cells using the Invitrogen
Lipofectamine 3000 Reagent protocol (ThermoFisher Scientific). The protocol was
scaled for 12 well plates. Additionally, puromycin was decided upon for antibiotic
selection. Approximately 1.8 x 105 cells were plated for 70-90% confluency the next day.
Three experiments were set-up with three different conditions: 1.24µL of
lipofectamine 3000 per well and 4µg/mL of puromycin, 2.47µL of lipofectamine 3000
per well a 2µg/mL of puromycin, and 2.47µL of lipofectamine 3000 and 4µg/mL of
puromycin. The conditions were selected based upon the Invitrogen procedure and a
preliminary experiment which showed early cell death that was thought to be due to
either the lipofectamine or the puromycin. Each experiment contained a well of cells that
would not be transfected but would be selected with antibiotic. Each experiment also
contained one well of cells that received the original vectors and one well of cells that
received the engineered sgRNA scaffold and pFETCH with the appropriate HOM arms.
The experiment with the greater amount of Lipofectamine 3000 also contained a well of
cells transfected with green fluorescent protein (GFP) to determine transfection efficiency
of the lower amount. The greater amount of Lipofectamine 3000 was shown to have a
transfection efficiency of 45% from an earlier experiment done by another member of the
lab, Bella Kohrs. Invitrogen procedure was followed and 48 hours after transfection,
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complete growth medium containing the appropriate concentration of puromycin was
added to the wells that underwent transfection except for the well transfected with GFP.
The well transfected with GFP was visualized with blue light. Antibiotic selection lasted
three days. Due to cell death, experiments were unable to continue and visualization did
not occur.

mRNA quantification
To determine the relative amounts of PKHD1L1 within normal human cells, we
needed to isolate the PKHD1L1 mRNA and do qPCR. RNA was isolated from HEK 293
cells and AG11138 cells using a ThermoScientific GeneJET RNA Purification Kit and its
accompanying protocol (ThermoScientific). RNA concentration was determined using a
the nanodrop feature of a BioTek synergy multi-mode reader and then diluted to create a
50ng solution of each RNA extraction.
B-actin was used as a control and primers were created for B-actin and for
PKHD1L1. PKHD1L1 primers were created using Primer3 (Primer3, bioinfo.ut.ee). The
parameters used were between 18 and 30 base pairs (bp’s) in length, a melting point
between 60°C and 64°C, and a GC content between 35-65%. Amplicon length should be
less than 500bp’s in length.
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Table 2. Genes and respective primers for qPCR.
Gene

Primer

Sequence (5’ to 3’)

Melting GC
Point

content
(%)

B-actin

Forward

AGTTGAAGGGAATAATGTCACACTGG 59.1°C

54.55

B-actin

Reverse

AGTTGAAGGGAATAATGTCACACTGG 60.6°C

54.55

PKHD1L1 Forward CACCATTGGCAATGAGCGGTTC

61.25°

42.31

PKHD1L1 Reverse

61.64°

50.00

AGGTCTTTGCGGATGTCCACGT

For qPCR, primers were diluted to 10µM concentrations and master-mixes were
created for B-actin and PKHD1L1, respectively, using AzuraQuant 1-Step Green LoRox
and AzuraSpring RTase (Azura Genomics).

Table 3. Master-mix amounts and products for 12 reactions (six of each gene with
one extra reaction’s worth of materials).
B-actin
•
•
•
•

PKHD1L1
70ul one-step qPCR mix
5.6ul Forward B-actin primer
(10uM)
5.6ul Reverse B-actin primer
(10uM)
7ul 20x RTase

•
•
•
•

70ul one-step qPCR mix
5.6ul Forward PKHD1L1 primer
(10uM)
5.6ul Reverse PKHD1L1 primer
(10uM)
7ul 20x RTase

15

12 tubes were created, with three replicates of B-actin and PKHD1L1 for each cell line.
For each tube, 12.6µL of the appropriate master-mix, 50ng of the appropriate RNA, and
PCR grade H2O as needed for a 20µL reaction was added to each tube. qPCR was run
using a MyGo Mini S Real-Time PCR machine by Azura Genomics with the following
program:
1. 50°C for ten minutes
2. 95°C for two minutes
3. 95°C for 5 seconds then62°C for 25 seconds
4. Repeat step three for 39 more cycles
Data was collected and Delta Ct numbers calculated by subtracting average B-actin Ct
values from average PKHD1L1 Ct values for each cell type.

Data analysis
Data analysis was done using JMP Pro Version 15 to run ANOVA’s and post-hoc
tests if necessary. JMP Pro was also used to create graphs shown. Delta Ct numbers were
calculated using Microsoft Excel Version 16.4821041102.

Results
MTS and Colony Formation Assay on PKHD1L1 knockouts in UM-UC-3 cells
An MTS assay was done on two different densities of parental and mutant cells
(1.0x104 and 1.3x104 per well in a 96 well plate). The cells at the lower density showed
no significant difference between parental and mutant cells at the same time points,
although there was a significant difference between time points within cell type
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(p<0.001) (Figure 1). The cells at the greater density (1.3x104) did show a significant
difference between parental and mutant cells at the same time points, with the mutant
cells showing significantly greater absorbance at each time period than the parental cells
(p<0.0001) (Figure 2). This shows that that the PKHD1L1 mutant cells proliferate at a
greater rate than the parental cells, although there may be some dependence on density.
A colony formation assay was also performed on the parental and mutant UMUC-3 cells at either 100 or 200 cells per well in a six well plate. Colony counts varied
greatly and there were no significant differences between mutant and parental cells at
either density. Although neither are significant, at 100 cells per well there were fewer
colonies of the mutant cells while at 200 cells per well there were fewer colonies of the
parental cells (Figure 3).
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Mean

0.7

C

C

0.6

B

B

Absorbance

0.5

0.4

0.3
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Parental, 2 hr
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Figure 1. Normalized mean absorbance values of UM-UC-3 mutant and parental
cells with MTS solution added. Cell density for both parentals and mutants was 1.0 x
104 cells per well. Absorbance measured at three different times (1 hour, 2 hours, and 3
hours). Differing letters show significant difference (p<0.001). Error bars are standard
error.
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Figure 2. Normalized mean absorbance values of UM-UC-3 mutant and parental
cells with MTS solution added. Cell density for both parentals and mutants was 1.3 x
104 cells per well. Absorbance measured at three different times (1 hour, 2 hours, and 3
hours). Differing letters show significant difference (p<0.001, p= 0.007 for A and E).
Error bars are standard error.
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Figure 3. Colony count for mutant and parental UM-UC-3 cells plated at different
densities. There was no significant different between mutant and parental cells at each
plating density. Error bars are standard error.

Creating sgRNA scaffold for PKHD1L1
The target sequence was successfully cloned into an sgRNA scaffold. Primers
were cloned into plasmid pSpCas9(BB)-2A-Puro (PX459) V2.0 (AddGene). The plasmid
was then transformed into E. coli and purified DNA digested with SacI and BbsI to
confirm identity. BbsI and SacI cut sites are 245, 267 and 3606, 6204 respectively
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(Figure3). Oligos 1 and 2 were successfully cloned in twice and oligo 3 was successfully
confirmed three times, as shown by lanes 3, 4, 7, 8, 10, 11, and 12 (Figure 4).

Figure 3. Plasmid map for pSpCas9(BB)-2A-Puro (PX459) V 2.0 (AddGene). Red
arrows show approximate BbsI cut sites (245, 267). Blue arrows show approximate SacI
cut sites (3606, 6204).
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Figure 4. Gel of modified pspCas9 PX459 plasmid digested with SacI and BbsI
enzyme along with accompanying ladder. Lanes 1-4 are Oligo 1, lanes 5-8 are Oligo 2,
and lanes 9-12 are Oligo 3 (Table 1).

Transfection
For all transfection conditions done, cells were unable to recover after three days
of antibiotic selection with puromycin. Cells at the lower concentration of puromycin
seemed to have greater survival than at the higher concentration but were still unable to
recover enough for antibody staining and visualization. Due to this, localization of
PKHD1L1 has yet to be determined.
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Quantifying PKHD1L1 Expression in HEK 293 and AG11138 cells
RT-qPCR was done using RNA from HEK 293 kidney cells and AG11138 breast
cells. Resulting Delta Ct numbers show relative PKHD1L1 expression for each cell type.
Delta Ct shows the difference in the number of cycles needed to reach threshold (Ct)
between the gene of interest (PKHD1L1) and the reference gene (beta-actin). A greater
Delta Ct means that there were lower amounts of RNA present. Delta Ct values are very
consistent across both cell type and the amount of RNA used in the reaction. This means
the relative expression of beta-actin was similar across both amounts of RNA. Relative
expression of PKHD1L1 was also similar between the differing RNA amounts. This
shows that expression of PKHD1L1 is similar across the two cell types and does not
depend greatly on the amount of RNA used (Table 3, Figure 5). The s-curves showing
intensity over time also depict consistency within both B-actin (control gene) and
PKHD1L1 (gene of interest) for both amounts of RNA used (Figure 6, Figure 7).

Table 4. Amount of PKHD1L1 RNA input into the reaction, cell type, and the
resulting Delta Ct from qPCR.
RNA amount

Cells

Delta Ct

40ng

AG11138

16.292

40ng

HEK 293

16.872

100ng

AG11138

18.254

100ng

HEK 293

16.935
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Delta Ct

20

Delta Ct

15

10

5

0

AG11138

HEK 293

AG11138

40ng

HEK 293
100ng

RNA amount (ng) / Cell type

Figure 5. Delta Ct values for different amounts of RNA and different cell types.
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Figure 6. S-curves for B-actin and PKHD1L1 when using 40ng of RNA. Graph
depicts intensity over number of cycles. The red box encloses the lines showing the
samples using B-actin primers while the blue box encloses the lines representing the
samples using PKHD1L1 primers.

Figure 7. S-curves for B-actin and PKHD1L1 when using 100ng of RNA. Graph
depicts intensity over cycle number. The red box encloses the lines showing the
samples using B-actin primers while the blue box encloses the lines representing the
samples using PKHD1L1 primers.
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Discussion
PKHD1L1 is a gene found to be highly mutated in different types of cancer,
including epithelial and breast cancers. This connection suggests that PKHD1L1 is a
tumor suppressor and that when the gene’s normal function is disrupted, there is a greater
likelihood of tumor occurrence. As such, it is important to learn about PKHD1L1 and its
role in tumors and tumor suppression. To do this, our lab conducted tests and examined
the data to begin to gain an understanding of how PKHD1L1 is related to tumors and
what its normal function is.

The Role of PKHD1L1 in Cell Proliferation
Preliminary knockouts of PKHD1L1 suggest that it plays a role in regulating cell
growth and proliferation. The MTS assay indicates that at a proper density, UM-UC-3
cells with PKHD1L1 knocked out proliferate at a greater rate than the normal UM-UC-3
cells (Figure 2). This suggests that PKHD1L1’s normal function may have to do with
limiting or regulating cell growth.
The colony formation assay results support this hypothesis, as at the greater
plating density, significantly more colonies were formed (Figure 3). This was not seen at
the 100 cells per six well density. This assay also seems to suggest that PKHD1L1 plays
an important role in limiting cell growth or regulating the cell cycle. It is important to
note, however, that there was much variation in the colony counts and thus the analysis
was done using averages.
Interestingly, both assays suggest that density is important for the effects of
mutant PKHD1L1 to be shown. Significant difference is only seen for the higher density
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conditions in each experiment. This leads us to believe that UM-UC-3 cells depend on
growth signals from other cells in order to grow properly. One paper found that in BSC-1
cells, epithelial cells from African green monkeys, that epithelial growth hormone (EGF)
receptors decrease at higher densities (Holley et al., 1977). This indicates that gene
expression does change based upon cell density and that they can sense cell density.
Keeping in line with this finding, if PKHD1L1 is believed to be involved in cell growth
regulation by limiting overgrowth, it would also make sense that the protein is mostly
needed at greater densities when cell growth should be limited. This would explain why
we see a correlation between cell density and a difference in cell growth between parental
and mutant cells. If this is true, it could mean that PKHD1L1’s expression is linked to
cell density.
While these findings indicate that the knockout of PKHD1L1 changes the rate of
cell growth, the knockout could only be confirmed on the DNA level. Although
sequencing confirmed that the desired target had been knocked out, we were unable to
determine whether or not this led to the protein being created at all. Antibody staining for
the protein was inconclusive, meaning that although our results show significant
differences between the mutant and parental cells, we cannot be sure that this is actually
due to the successful knock-out of PKHD1L1.
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Tagging PKHD1L1 Using CRISPR-Cas9
In order to determine where PKHD1L1 is located within a cell, we decided to
engineer a FLAG-tag into the gene. In order to begin, an sgRNA scaffold must be created
with the proper target sequence cloned in. This was done with the PKHD1L1 primers
used shown in Table 1. After cloning the oligos in, plasmids were transformed into E.
coli. The E. coli did not grow the first few times, so the target sequence cloning protocol
was modified. Plasmid was digested with BbsI for up to four hours to ensure full cutting
and NEB 10-beta E. coli optimized for larger plasmids were used. The plasmid contained
ampicillin resistance, and one of the surviving cells was selected, grown, and purified
DNA was then digested with SacI and BbsI to determine success. Successful cloning was
found at least once for all three oligos. Success was determined by running an
electrophoresis gel. Because the primers were cloned into the plasmid using the BbsI cut
site, if cloning was successful then the BbsI cut site will no longer exist. Thus, during the
diagnostic digest the plasmid will only cut at the SacI site. This will result in two
differently sized pieces of DNA, one about 2600 bp’s long and the other about 6600 bp’s
long. Unsuccessful plasmid creation will result in two or three visible bands of DNA
segments of about 2600, 3200, and 3300 bp’s long. The plasmid created using “Oligo 1”
was selected for use in the transfection of HEK 293 and AG11138 cells.

Transfection of CRISPR/Cas plasmid system and immunofluorescence
Another student in the lab, Bella Kohrs, created a plasmid with the proper
homology arms and selection marker. This, along with the synthesized gRNA and Cas9
vector, would be transfected into HEK 293 cells. Puromycin was used to select for
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successfully transfected cells, with the amount determined by a kill curve done on normal
HEK 293 cells. The selection with puromycin was found to be too harsh when combined
with transfection and so staining was not possible within the time frame of this project.
Kohrs, however, was able to stain and image a transfection done with G418. The staining
was inconclusive. Combined with the earlier results implicating cell density as being an
important factor in PKHD1L1 expression, it may be worthwhile to do another
transfection with a greater number of cells at time of staining.

mRNA Expression of PKHD1L1 within HEK 293 and AG11138 cells
Purification and amplification of PKHD1L1 RNA through qPCR revealed that
there are quantifiable levels of PKHD1L1 expressed in both HEK 293 and AG11138
cells. Expression was low compared to the housekeeping gene used, beta-actin. Corrected
delta-Ct values show that PKHD1L1 expression does not significantly differ between cell
lines nor between the amount of RNA put into the reaction. This shows that PKHD1L1 is
expressed in normal human cells. Given the possibility of PKHD1L1 being density
dependent, it would be interesting to isolate RNA from cells at differing levels of
confluency and then run RT-qPCR to determine how this affects expression levels. This
could provide further information on PKHD1L1’s role regarding cell proliferation.
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Future projects and areas of interest
These results demonstrate only the beginnings of knowledge about PKHD1L1’s
function and localization. The results, when taken collectively, suggest that PKHD1L1
may play a role in limiting cell growth. This role may also be correlated to cell density.
This raises the question of whether or not PKHD1L1 is actually affected by cell density.
More experiments done with different densities of cells could help confirm or deny this.
Creating successful knockouts of PKHD1L1 that could be verified on the protein level
would also lead to better conclusions on the role of PKHD1L1.
Additionally, information on the localization of PKHD1L1 is still quite sparse.
Additional transfections should be run using the FLAG-tag CRISPR/Cas9 system in
order to achieve more clear staining. Once localization can be discovered, assays can be
tailored more closely to probably function.
The preliminary results found during this project are promising and show
potential for PKHD1L1 being an important gene in tumor suppression. Determining its
localization and function could not only increase knowledge on contributing factors of
tumor formation but also help reveal more about cell growth regulation. Hopefully, the
findings of this project can help guide further research on PKHD1L1 and tumor
suppression in general.
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